Lenzetto

Estradiol, the active ingredient in Lenzetto, is an estrogen presented as a transdermal patch for transdermal use. It is prescribed to manage menopausal vasomotor symptoms and to treat estrogen deficiency in women. The patch delivers estradiol systemically, providing steady hormone levels without first‑pass metabolism.

GNH USA supplies Lenzetto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with capabilities for bulk and individual packaging. The company adheres to EU quality standards and provides regulatory support for importers.

Lenzetto, an estradiol transdermal system, is used to address conditions related to estrogen deficiency.

- Menopausal vasomotor symptoms: reduces frequency and severity of hot flashes and night sweats. - Estrogen deficiency: restores systemic estrogen levels, alleviating symptoms such as vaginal dryness and mood changes. - Postmenopausal bone health: helps maintain bone mineral density and reduces risk of osteoporosis progression.

Adverse reactions to Lenzetto may vary in frequency and severity.

Common Side Effects: - Skin irritation at the application site: redness, itching or rash. - Headache: mild to moderate intensity. - Nausea: occasional feeling of queasiness. - Breast tenderness: mild swelling or discomfort.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Stroke or transient ischemic attack: neurological events. - Gallbladder disease: biliary colic or cholecystitis. - Hormone‑dependent cancer progression: potential worsening of breast or endometrial cancer.

Before prescribing Lenzetto, clinicians should consider several safety precautions.

- Contraindicated in women with known estrogen‑dependent malignancies: avoid use. - Assess thromboembolic risk: do not use in patients with history of DVT, PE, or clotting disorders. - Monitor liver function: adjust therapy if severe hepatic impairment is present. - Evaluate cardiovascular status: caution in smokers or those with uncontrolled hypertension. - Review breast health: perform regular examinations and imaging as indicated. - Store at room temperature: keep in original pouch, protect from light and moisture.

Lenzetto can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Combined estrogen‑containing contraceptives: increased risk of thromboembolism. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect, requiring monitoring. - Cytochrome P450 3A4 inducers (e.g., rifampin, carbamazepine): reduce estradiol plasma levels, decreasing effectiveness.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: estradiol may diminish blood pressure‑lowering effect. - Thyroid hormone replacement: estradiol can increase thyroxine binding, possibly requiring dose adjustment. - Certain antiepileptic drugs (e.g., phenytoin): may lower estradiol concentrations. - SSRIs and SNRIs: may increase risk of serotonin syndrome when combined with high estrogen doses.